Burning Rock Biotech (BNR) Gross Margin (2019 - 2025)

Burning Rock Biotech's Gross Margin history runs 7 years deep, the most recent figure standing at 78.03% for Q4 2025.

• In Q4 2025, Gross Margin rose 707.0% year-over-year to 78.03%; the TTM figure through Dec 2025 stood at 74.7% (up 443.0% YoY), while the FY2025 annual figure was 74.67%, up 442.0% from the prior year.
• Gross Margin was 78.03% for Q4 2025 at Burning Rock Biotech, up from 75.1% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 78.03% in Q4 2025 to a low of 63.13% in Q2 2022.
• Historically, Gross Margin has averaged 70.3% across 5 years, with a median of 70.93% in 2021.
• The sharpest annual moves came in 2022 and 2025: Gross Margin plunged 777 bps in 2022, then surged 707 bps in 2025.
• A 5-year view of Gross Margin shows it stood at 71.52% in 2021, then fell by 0 bps to 71.2% in 2022, then dropped by 9 bps to 64.51% in 2023, then increased by 10 bps to 70.96% in 2024, then increased by 10 bps to 78.03% in 2025.
• The last three Gross Margin figures came in at 78.03% (Q4 2025), 75.1% (Q3 2025), and 72.77% (Q2 2025), per Business Quant data.